Rosine Guimbaud
A5091297068- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Screening and Detection
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal Tumor Research and Treatment
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Surgical Treatments
- Neuroblastoma Research and Treatments
- Esophageal Cancer Research and Treatment
- Metastasis and carcinoma case studies
- Inflammatory Bowel Disease
- Microscopic Colitis
- Renal cell carcinoma treatment
- Anorectal Disease Treatments and Outcomes
- Gastrointestinal Bleeding Diagnosis and Treatment
Centre Hospitalier Universitaire de Toulouse
2016-2025
Hôpital Rangueil
2016-2025
Institut Claudius Regaud
2013-2024
Inserm
2013-2024
Centre de Recherche en Cancérologie de Toulouse
2005-2024
Université Toulouse III - Paul Sabatier
2013-2024
Université de Toulouse
2014-2024
Hôpital Larrey
2013-2024
Digestive Health Research Institute
2024
Institut universitaire du cancer de Toulouse Oncopole
2018-2024
Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting oxaliplatin, irinotecan, fluorouracil, leucovorin (FOLFIRINOX) as compared with gemcitabine first-line therapy in patients metastatic pancreatic cancer.We randomly assigned 342 an Eastern Cooperative Oncology Group performance status score 0 or 1 (on scale to 5, higher scores indicating greater severity illness) receive FOLFIRINOX (oxaliplatin, 85 mg per square meter body-surface area; 180 meter;...
Providing accurate estimates of cancer risks is a major challenge in the clinical management Lynch syndrome.To estimate age-specific cumulative developing various tumors using large series families with mutations MLH1, MSH2, and MSH6 genes.Families syndrome enrolled between January 1, 2006, December 31, 2009, from 40 French genetics clinics participating ERISCAM (Estimation des Risques de Cancer chez les porteurs mutation gènes MMR) study; 537 segregating mutated genes (248 MLH1; 256 MSH2;...
KEYNOTE-164 (NCT02460198) evaluated the antitumor activity of pembrolizumab in previously treated, metastatic, microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC).This phase II open-label study involved 128 centers worldwide. Eligible patients were age ≥ 18 years and had metastatic MSI-H/dMMR CRC treated with 2 prior lines standard therapy, including fluoropyrimidine, oxaliplatin, irinotecan or without anti-vascular endothelial growth...
Complete resection of liver metastases colorectal origin is the only potentially curative treatment. In order to decrease recurrences, use adjuvant systemic chemotherapy after controversial because no randomized study demonstrated its benefit.In a multicenter trial, we randomly assigned 173 patients with completely resected (R0) hepatic from cancer surgery alone and observation (87 patients) or followed by 6 months fluorouracil folinic acid monthly regimen (86 patients). The main outcome...
To compare the quality of life (QoL) patients receiving oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) or gemcitabine as first-line chemotherapy to assess whether pretreatment QoL predicts survival in with metastatic pancreatic cancer.Three hundred forty-two performance status 0 1 were randomly assigned receive FOLFIRINOX (oxaliplatin, 85 mg/m(2); 180 leucovorin, 400 mg/m(2) bolus followed by 2,400 46-hour continuous infusion, once every 2 weeks) 1,000 weekly for 7 8...
To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, irinotecan (FOLFIRI) as first-line treatments in patients advanced gastric or esophagogastric junction (EGJ) adenocarcinoma.This open, randomized, phase III study was carried out 71 centers. Patients locally metastatic EGJ cancer were randomly assigned to receive either ECX treatment (ECX arm) FOLFIRI (FOLFIRI arm). Second-line predefined for the arm The primary criterion time-to-treatment failure (TTF)...
Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment modified FOLFIRINOX vs gemcitabine in patients resected pancreatic ductal adenocarcinoma; mature data are now available.To report 5-year outcomes and explore prognostic factors for overall survival.This open-label, phase was conducted 77 hospitals France Canada included aged 18 to 79 histologically confirmed adenocarcinoma who had undergone...
There is no molecular biomarker available in the clinical practice to assess prognosis of advanced pancreatic carcinoma. This multicenter prospective study aimed investigate role KRAS mutation subtypes within primary tumor determine cancer.The exon-2 status was tested on endoscopic ultrasound-guided fine-needle aspiration biopsy material (primary tumor; restriction fragment-length polymorphism plus sequencing and TaqMan allelic discrimination) patients with proven locally and/or metastatic...
Sporadic early onset colorectal carcinoma (EOCRC) which has by definition no identified hereditary predisposition is a growing problem that remains poorly understood. Molecular analysis could improve identification of distinct sub-types cancers (CRC) with therapeutic implications and thus can help establish sporadic EOCRC entity. From 954 patients resected for CRC at our institution, 98 were selected. Patients aged 45–60 years excluded to define "young" "old" groups. Thirty-nine cases...
3071 Background: Mismatch repair deficient cancers harbor high levels of microsatellite instability and somatic mutations. Treatment with anti-PD-1 antibodies has resulted in durable objective responses MSI-H cancer. As part the ongoing, global, multicenter phase 2 studies KEYNOTE(KN)164 KN158, we assessed efficacy pembrolizumab patients (pts) tumors. Methods: Both enrolled pts status determined locally by IHC or PCR. KN164 CRC ≥2 prior therapies, whereas multicohortKN158 study included...
Refractory hypoglycemia in patients with metastatic insulinoma is an important cause of morbidity and mortality. Everolimus could be a new therapeutic option.Within the French Group, we conducted retrospective, multicentric study endocrine tumors to evaluate time first recurrence symptomatic hypoglycemia, after everolimus initiation, refractory hypoglycemia. Ongoing hyperglycemic medical options, tumor response, safety information were recorded.Twelve who treated between May 2007 June 2011...
This phase 1 trial was aimed to determine the safety, pharmacokinetics, and preliminary clinical activity of CYL-02, a nonviral gene therapy product that sensitizes pancreatic cancer cells chemotherapy. CYL-02 administrated using endoscopic ultrasound in 22 patients with concomitantly received chemotherapy (gemcitabine). The maximum-tolerated dose (MTD) exceeded maximal feasible not identified. Treatment-related toxicities were mild, without serious adverse events. Pharmacokinetic analysis...
The management of patients with colorectal cancer (CRC) and potentially resectable liver metastases (LM) requires quick assessment mutational status response to pre-operative systemic therapy. In a prospective phase II trial (NCT01442935), we investigated the clinical validity circulating tumor cell (CTC) DNA (ctDNA) detection. CRC LM were treated first-line triplet or doublet chemotherapy combined targeted CTC (Cellsearch®) Kirsten RAt Sarcoma (KRAS) ctDNA (droplet digital polymerase chain...
PurposeThis Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy second-line advanced pancreatic adenocarcinoma.MethodsEligible patients were randomized 2:1 to either eryaspase gemcitabine or mFOLFOX6 (eryaspase arm), alone (control arm). Co-primary endpoints overall survival (OS) and progression-free (PFS) low asparagine synthetase (ASNS) expression. Secondary included OS PFS the entire population.Results141...
Spartalizumab, a humanized anti-programmed death protein 1 (PD-1) monoclonal antibody, was evaluated in patients with well-differentiated metastatic grade 1/2 neuroendocrine tumors (NET) and poorly-differentiated gastroenteropancreatic carcinomas (GEP-NEC). In this phase II, multicenter, single-arm study, received spartalizumab 400 mg every 4 weeks until confirmed disease progression or unacceptable toxicity. The primary endpoint overall response rate (ORR) according to blinded independent...
This randomized, open-label trial compared the efficacy and safety of adjuvant
Abstract Missense mutations in the polymerase epsilon (POLE) gene have been reported to generate proofreading defects resulting an ultramutated genome and sensitize tumors checkpoint blockade immunotherapy. However, many POLE-mutated do not respond such treatment. To better understand link between POLE mutation variants response immunotherapy, we prospectively assessed efficacy of nivolumab a multicenter clinical trial patients bearing advanced mismatch repair–proficient solid tumors. We...
Background Pemigatinib is approved for patients with pretreated, locally advanced or metastatic CCA harboring FGFR2 rearrangements fusions. We aim to assess the effectiveness and safety of pemigatinib in real-world setting. Material Methods A joint analysis two multicentre observational retrospective cohort studies independently conducted France Italy was performed. All consecutive FGFR2-positive affected by treated as second- further line systemic treatment clinical practice, within outside...